Why Is Boston Scientific Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Boston Scientific Corporation (NYSE:BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a treatment for patients with atrial fibrillation. The study demonstrated that the FARAPULSE PFA System was non-inferior to standard-of-care therapies. The potential FDA approval of Farapulse might bolster Boston Scientific's position in the electrophysiology market. BSX shares are up 5.54% at $53.57.
August 28, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's FARAPULSE PFA System shows promising results in ADVENT trial, which could lead to FDA approval and strengthen the company's position in the electrophysiology market. BSX shares are up 5.54%.
The positive results from the ADVENT trial of the FARAPULSE PFA System could lead to FDA approval, which would strengthen Boston Scientific's position in the electrophysiology market. This positive news is likely to have contributed to the rise in BSX's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100